enGene Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENGN research report →
Range $2 – $4
Price Chart
About the company
Operating through its subsidiary, enGene, Inc. , enGene Holdings Inc. functions as a clinical-stage biotechnology firm.
- CEO
- Ronald H. W. Cooper
- IPO
- 2022
- Employees
- 82
- HQ
- Montreal, QC, CA
Get TickerSpark's AI analysis on ENGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $119.24M
- P/E
- -1.35
- PEG
- 0.38
- P/S
- 0.00
- P/B
- 0.49
- EV/EBITDA
- -0.97
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -29.34%
- ROIC
- -23.70%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-123,165,000
- Net Income
- $-117,302,000-112.7%
- EPS
- $-2.29-56.8%
- OCF Growth
- -105.5%
- FCF Growth
- -104.7%
- 52W High
- $12.25
- 52W Low
- $1.40
- 50D MA
- $1.78
- 200D MA
- $5.97
- Beta
- -0.28
- RSI (14)
- 48
- Avg Volume
- 958.26K
No earnings-call transcripts are available for ENGN yet.
- Free Float
- 36.6%
- Shares Outstanding
- 66.99M
- Float Shares
- 24.51M
of shares held by institutions
59 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fcpm Iii Services B.V. | 9.63M | 0 |
| Bml Capital Management, LLC | 6.67M | ▲ 6.67M |
| Siren, L.L.C. | 6.26M | ▲ 1.00M |
| Perceptive Advisors LLC | 4.82M | ▼ 1.01M |
| Ameriprise Financial Inc | 2.68M | ▲ 2.68M |
| Nextech Invest, Ltd. | 2.32M | 0 |
| Adar1 Capital Management, LLC | 2.10M | ▲ 1.97M |
| Vestal Point Capital, LP | 1.67M | ▼ 497.57K |
| Acorn Capital Advisors, LLC | 1.27M | ▲ 1.27M |
| Peapod Lane Capital LLC | 1.10M | ▲ 1.10M |
| Balyasny Asset Management L.P. | 1.01M | ▼ 141.65K |
| Millennium Management LLC | 966.63K | ▲ 6.95K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 16, 26 | Chinoporos Constantine | other | 75,000 |
| Jul 16, 26 | Richton Kathleen P. | other | 0 |
| Jul 16, 26 | Richton Kathleen P. | other | 13,900 |
| Jul 16, 26 | Richton Kathleen P. | other | 105,000 |
| Jul 16, 26 | Richton Kathleen P. | other | 45,000 |
| Jun 16, 26 | Astley-Sparke Philip | other | 31,000 |
| Jun 16, 26 | BRUNK GERALD A | other | 31,000 |
| Jun 16, 26 | Glickman Richard M | other | 31,000 |
| Jun 16, 26 | Grossman William | other | 200,000 |
| Jun 16, 26 | Grossman William | other | 31,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENGN coverage
Recent articles, reports, and earnings notes.
No research on ENGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENGN report →Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
defenseworld.net · Aug 15
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
marketbeat.com · Aug 13
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
seekingalpha.com · Aug 11
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
businesswire.com · Aug 4
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
businesswire.com · Jul 16
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
globenewswire.com · Jul 15
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
businesswire.com · Jun 15
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
prnewswire.com · Jun 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.